Plaque psoriasis
Conditions
Interventions
Adalimumab group:None
Tildrakizumab group:None
Ixekizumab group:None
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients who visited the First Affiliated Hospital of Chongqing Medical University between January 2019 and July 2025. 2. Clinically diagnosed with psoriasis. 3. Received treatment with any class of biologic agent, such as secukinumab, guselkumab, tildrakizumab, ixekizumab, adalimumab, or ustekinumab.
Exclusion criteria
Exclusion criteria: 1. Age <= 18 years. 2. Diagnosed with active tuberculosis at enrollment. 3. Missing baseline screening data for latent tuberculosis infection. 4. Absence of any follow-up data on tuberculosis status after the baseline period. 5. Other types of psoriasis excluding plaque psoriasis (if plaque psoriasis combined with arthropathic psoriasis can be retained).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Latent Tuberculosis Reactivation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Seroconversion Rate in Baseline Positive Patients; | — |
Countries
China
Contacts
Public ContactHuang Kun
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed